MiNK outlines 90-patient randomized phase II ARDS trial with initial data expected in 2H 2026

Q1 2026 Management View Dr. Jennifer Buell (Co-Founder, President, CEO & Director) framed recent disclosures around clinical and mechanistic readouts across oncology and pulmonary indications, saying, ...
ascopubs.org

Dual targeting of VEGF and PD-1: A phase I/II trial of ivonescimab, a novel bispecific antibody, in recurrent glioblastoma.

Update on GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...